June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Scientific Considerations for In Vitro Bioequivalence Studies of Generic Cyclosporine Ophthalmic Emulsions
Author Affiliations & Notes
  • Darby Kozak
    Office of Generic Drugs, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Mohammad Absar
    Office of Generic Drugs, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Peter Petrochenko
    Office of Generic Drugs, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Xiaoming Xu
    Office of Pharmaceutical Quality, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Jiwen Zheng
    Office of Science and Engineering Laboratories, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Yong Wu
    Office of Science and Engineering Laboratories, US Food and Drug Administration, Silver Spring, Maryland, United States
  • Footnotes
    Commercial Relationships   Darby Kozak, None; Mohammad Absar, None; Peter Petrochenko, None; Xiaoming Xu, None; Jiwen Zheng, None; Yong Wu, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 493. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Darby Kozak, Mohammad Absar, Peter Petrochenko, Xiaoming Xu, Jiwen Zheng, Yong Wu; Scientific Considerations for In Vitro Bioequivalence Studies of Generic Cyclosporine Ophthalmic Emulsions. Invest. Ophthalmol. Vis. Sci. 2017;58(8):493.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, the FDA recommends two options to demonstrate bioequivalence (BE) for cyclosporine ophthalmic emulsion (COE): (1) a clinical endpoint study or (2) in vitro studies with comparative physicochemical characterization. As the in vitro option relies on demonstrating product sameness, the FDA requires generics approved by this option be formulated qualitatively and quantitatively similar to the reference product. A summary of scientific considerations when conducting studies to support the in vitro option was compiled and certain complex parameters such as particle size and viscosity were evaluated.

Methods : For development of the in vitro option, a systematic approach was adopted to identify the physicochemical parameters that are critical to the COE formulation properties as well as considerations of analytical and compartive methods. Particle size distribution (PSD) at different dilutions was measured using dynamic light scattering, laser diffraction and transmission electron microscopy (TEM). Both negative staining TEM and cryo-TEM – was used to measure globule size and morphology of the formulation. A full viscosity profile as a function of applied shear was measured using a cone-and-plate geometry.

Results : In addition to product manufacturing conditions, analytical procedures can impact the measured physicochemical properties of COE. COE appears to have a polydisperse/multimodal PSD, which can range from a few nanometers up to a micron depending on the instrument and sample preparation. As such complementary analytical sizing methods are recommended as no one single method may be suitable to measure the entire size range. In addition, more complex histogram analysis, such as earth mover’s distance, is suggested for comparing PSD sameness. Finally, the COE formulation is non-Newtonian shear-thinning; therefore, viscosity profiles as a function of applied shear rate are recommended.

Conclusions : The BE guidance on COE provides further essential details on the in vitro study parameters and evaluation criteria. Due to the polydisperse nature of COE (ex. oil globules, micelles) and presence of a carbomer copolymer excipient, special considerations must be employed for particle size and viscosity measurements as well as in the method for comparative analysis to ensure generic and reference product sameness.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×